Revolutionising Early-Stage Breast Cancer Treatment: How the MAF Test® Enhances Precision Care with Biomarker-Driven Insights

The MAF Test® by Inbiomotion is an advanced diagnostic tool designed to enhance treatment decisions in early-stage breast cancer. By detecting MAF gene amplification, the test provides oncologists with critical insights into a patient’s risk of developing bone metastasis. This information is vital for identifying patients who may benefit from bisphosphonate therapy, such as zoledronic acid, allowing for more personalized and effective treatment plans.

MAF gene status plays a pivotal role in guiding bisphosphonate therapy. Studies have shown that MAF-negative patients are more likely to benefit from bisphosphonates, experiencing a reduced risk of bone metastasis and improved outcomes. On the other hand, MAF-positive patients may not benefit from bisphosphonates and, in some cases, could even be harmed by such treatment. Therefore, identifying MAF status through the MAF Test® is essential for ensuring that the right patients receive the appropriate therapy, optimizing the benefit-risk ratio.

Traditional breast cancer treatment guidelines often consider imprecise factors like menopausal status for patient stratification. However, these factors, while useful, may not always capture the full complexity of an individual patient’s cancer. However, the MAF Test® offers a more precise, biomarker-driven approach, empowering oncologists to make decisions based on the specific biological characteristics of the cancer. This advancement not only aligns with current ESMO/ASCO guidelines but also enhances them, leading to improved patient outcomes.

Precision Stratification: Accurately identifies patients at higher risk of relapse and death.

Clinical Impact: Helps optimize the use of bisphosphonates, leading to better patient outcomes.

Biomarker-Driven Insights: Moves beyond traditional stratification methods, offering a personalized approach to treatment.

Source BioScience, an industry-leading provider of genomic services and healthcare diagnostics, and Inbiomotion, have signed an exclusive agreement to start offering the MAF Test® as a service in United Kingdom and Ireland.